728 results on '"Kerr, Keith M"'
Search Results
2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx
3. ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project
4. Rediscovering immunohistochemistry in lung cancer
5. The evolution of non-small cell lung cancer metastases in TRACERx
6. The evolution of lung cancer and impact of subclonal selection in TRACERx
7. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
8. An endogenous inhibitor of angiogenesis downregulated by hypoxia in human aortic valve stenosis promotes disease pathogenesis
9. Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
10. Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
11. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
12. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
13. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
14. Molecular testing in stage I–III non-small cell lung cancer: Approaches and challenges
15. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
16. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC
17. PD-L1 as a biomarker of response to immune-checkpoint inhibitors
18. Basaloid Carcinoma, Lung
19. Squamous Cell Papilloma, Lung
20. Sclerosing Pneumocytoma, Lung
21. Atypical Adenomatous Hyperplasia, Lung
22. Mucous Gland Adenoma, Lung
23. Multifocal Micronodular Pneumocyte Hyperplasia
24. Mucoepidermoid Carcinoma, Lung
25. Minute Meningothelial Nodules
26. Minimally Invasive Adenocarcinoma (MIA)
27. Adenosquamous Carcinoma, Lung
28. Adenocarcinoma In Situ
29. Adenocarcinoma, Lung
30. Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy
31. The 2015 World Health Organisation Classification of Lung Cancer
32. Precision Medicine in Lung Cancer
33. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee
34. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
35. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer
36. Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
37. Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I–III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort
38. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
39. Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC
40. Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists
41. 222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816
42. Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization
43. Granular Cell Tumor
44. Clear Cell Tumor, Lung
45. Mixed Squamous Cell and Glandular Papilloma
46. Acinic Cell Tumor, Lung
47. Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth
48. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
49. Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry — Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort
50. Optimizing tissue stewardship in non‐small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.